Regulation of human type I procollagen gene expression was studied in cultured fibroblasts both at the transcriptional and posttranscriptional level. Transcriptional regulation was examined in cultures transfected with a human proa2(I) collagen promoter/reporter gene (chloramphenicol acetyltransferase) construct, while posttranscriptional regulation was assessed by parallel determinations of type I procollagen mRNA steadystate levels. Transforming growth factor-j01 (TGF-,81) elicited a marked, -5-23-fold, enhancement of proa2(I) collagen promoter activity, which was accompanied by an elevation of type I procollagen mRNA levels. This enhancement of gene expression was suppressed by tumor necrosis factor-a (TNF-a) and interferon-'y (IFN-"y), as determined at mRNA steady-state level, but two distinct mechanisms were involved. TNF-a suppressed the proa2(I) collagen promoter activity, whereas IFN-'y had only a minimal effect at transcriptional level. The effects of TNF-a and IFN--y were synergistic, suggesting that combination of these two factors may potentially provide pharmacologic means to counteract tissue deposition of collagen in diseases involving TGF-f,. (J. Clin. Invest. 1990.
Introduction
The synthesis and accumulation of connective tissue components of the extracellular matrix play a crucial role in biological situations involving tissue development, homeostasis, and repair. An aberration ofthese processes may also lead to development of pathological conditions, as in case of fibrotic diseases (1, 2) . Recently, a number of polypeptide growth factors have been shown to modulate the growth and migration of connective tissue derived cells, as well as the synthesis of extracellular matrix components, such as the collagens (3) (4) (5) . For example, proliferation of fibroblasts, the mesenchymal cell responsible for extracellular matrix production in the skin and other connective tissues, has been shown to be markedly stimulated by several growth factors, including transforming Receivedfor publication 13 April 1990 and in revisedform 22 June 1990. growth factor B1 (TGF-#31)I (5, 6) . The expansion of fibroblast populations in the tissues may then contribute to deposition of extracellular matrix components in the affected organs.
Certain growth factors have also been shown to enhance the expression of the extracellular matrix genes by individual connective tissue cells. In particular, TGF-3 has been shown to be a potent stimulator of collagen synthesis by fibroblasts in a variety ofexperimental conditions both in vivo and in vitro (5, 7) . Specifically, TGF-,3 enhances the synthesis of collagens type I and III, as well as of fibronectin, an abundant noncollagenous glycoprotein (7) (8) (9) (10) . Enhanced collagen and fibronectin gene expression by TGF-#3 has been shown to be accompanied by similar increases in the corresponding mRNA steadystate levels, suggesting transcriptional activation of the corresponding genes (7) (8) (9) (10) . A previous study using a chimeric mouse proa2(I) collagen promoter/reporter gene construct has shown enhancement of transcriptional activity by TGF-,B in mouse NIH-3T3 cells (1 1) . In addition to TGF-f3, other polypeptide growth factors are able to modulate collagen synthesis. For example, interleukin 1 has been shown to enhance collagen production by dermal fibroblasts at pretranslational level (12) (13) (14) . In contrast, tumor necrosis factor-a (TNF-a) and interferon-y (IFN-'y) suppress collagen synthesis (15) (16) (17) (18) , although platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) have apparently little, if any, effect in vitro (7) . Relatively little is known of the mechanisms by which these growth factors modulate the expression of collagen genes.
Several recent studies have provided evidence that activation of type I collagen gene expression by fibroblasts plays a crucial role in the development of dermal fibrosis in diseases, such as scleroderma, eosinophilic fasciitis, and keloids (19) (20) (21) (22) . The role of TGF-f3 in the pathogenesis of the fibrotic conditions has been emphasized, but relatively little is known about interactions of TGF-/ and other growth factors with respect to collagen gene expression.
We have recently demonstrated that the 3.5-kb upstream sequence of the proa2(I) collagen gene, linked to the chloramphenicol acetyltransferase (CAT) reporter gene, contains all elements necessary for high, tissue-specific transcription (23). In contrast, transfection experiments with a human proal(I) collagen promoter/CAT construct did not provide similar evidence of tissue specific expression (23). Thus, in this study we utilized the proa2(I) collagen promoter/CAT plasmid, 1. Abbreviations used in this paper: bFGF, basic fibroblast growth factor; CAT, chloramphenicol acetyltransferase; EGF, epidermal growth factor, GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IGF-I, insulin-like growth factor I; PDGF, platelet-derived growth factor; TGF, transforming growth factor; TNF, tumor necrosis factor. pMS-3.5/CAT, as a tool to study transcriptional regulation of type I collagen gene expression. Specifically, we have examined the potential interactions of TGF-fl1 with TNF-a and IFN-'y in modulating collagen gene expression. We have also examined four other polypeptide growth factors for their effects on human proa2(I) collagen promoter activity in cultured fibroblasts.
Methods
Transient transfections of cultured cells. Human skin fibroblast cultures were established from tissue specimens obtained from cosmetic surgery procedures, and utilized in passages 3-8. The cell cultures were maintained in Dulbecco's modified Eagle's medium (DME) supplemented with 10% fetal calf serum, 2 mM glutamine, 100 U/ml penicillin, and 50 gg/ml streptomycin. Mouse NIH-3T3 cells were purchased from American Type Culture Collection, Rockville, MD, and maintained in DME supplemented with 10% calf serum, 2 mM glutamine, and the antibiotics indicated above.
The The following cDNAs were used for Northern hybridizations: For proal(I) collagen mRNA, a 1.5-kb human cDNA (Hf677); for proa2(I) collagen mRNA, a 2.9-kb cDNA (Hfl 132) (29, 30) ; for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, a 1.3 kb rat cDNA (pRGAPDH 13) (31).
Growth factors and cytokines. The following growth factors and cytokines were used in these studies. TGF-f1 was kindly provided by Dr. David R. Olsen, Collagen Corporation, Palo Alto, CA; human recombinant IFN-'y, TNF-a, basic fibroblast growth factor (bFGF), mouse EGF, and porcine PDGF were purchased from BoehringerMannheim Biochemicals, Indianapolis, IN; human recombinant insulin-like growth factor I (IGF-I) was purchased from Collaborative Research, Bedford, MA.
In transient cell transfection experiments, the growth factors were added to the cell culture media 3 h after the glycerol shock, and the incubations were continued for an additional 40 h before assay ofCAT activity. The transfection efficiencies in cultures incubated with the growth factors were checked by assay of relative plasmid copy numbers, as described previously (32) . In cultures used for determination of mRNA steady-state levels by Northern analyses, the growth factors were added to the cultures at early confluency, and the incubations were continued for 24 h before isolation of total cellular RNA.
Results
Modulation of human proa2(I) collagen promoter activity by TGF-f31. A human collagen promoter/reporter gene construct pMS-3.5/CAT, which contains 3.5 kb of 5'-flanking sequences of proa2(I) collagen (COLIA2) gene linked to the CAT gene, was previously shown to exhibit high, tissue-specific transcriptional activity (23). This chimeric construct was used in this study for transient cell transfection experiments to determine the effects of TGF-(#l on type I collagen promoter activity.
Preliminary experiments showed that significant CAT activity could be detected in human skin fibroblasts and in mouse NIH-3T3 cells at 24-72 h ofincubation after transfection (26) .
The effects of TGF-# 1 were first tested by adding varying concentrations of this growth factor to the incubation medium of NIH-3T3 cells at 3 h after the glycerol shock. After an additional 40-h incubation, the cells were harvested and the CAT activity was measured as an index of the promoter activity.
The results indicated that TGF-# 1, in the concentration range of 0.1-10 ng/ml, significantly enhanced the activity of the proa2(I) collagen promoter in an apparently dose-dependent manner (Fig. 1 A) . Quantitation of the data by liquid scintillation counting (see Methods) revealed that the highest promoter activity, -23-fold higher than found in the untreated control cells, was noted with 5 ng/ml of TGF-#1, while increasing the concentration to 10 ng/ml did not further enhance the activity (Fig. 1 B) . Assay of plasmid copy number (32) in cultures incubated with and without TGF-#l did not reveal any differences (data not shown). Thus, in subsequent experiments either 5 or 10 ng/ml of TGF-#31 was used.
Parallel transfections with the promoterless pBSOCAT construct (26) revealed minimal CAT activity in NIH-3T3 cells, and incubation of cells transfected with this construct with 10 ng/ml of TGF-# I did not significantly increase the activity (Table I) . Also, expression of pSV2CAT, a positive control plasmid containing SV40 early region promoter linked to the CAT gene (25) , was unaffected by the addition of TGF-,B1 (Table I) . Thus, the enhancement of human proa2(I) collagen promoter activity appeared to be specific and to depend on the presence of TGF-( I responsive elements within the 3.5 kb of sequence flanking the 5'-end of the proa2(I) collagen gene. In addition, these results suggested that TGF-4t1 does not modulate the stability of CAT mRNA or protein, but that the in-1490 crease in CAT activity detected in transfected cells exposed to TGF-Il reflects stimulation ofthe proa2(I) collagen promoter transcriptional activity.
To examine the concomitant effect of TGF-f1 on the endogenous expression oftype I collagen genes, the proa 1(I) and proa2(I) collagen mRNA abundance was determined. Incubation of cultured human skin fibroblasts with TGF-# 1 (5 ng/ml) for a period of 24 h resulted in a marked increase in the steady-state levels of both these mRNAs ( Fig. 2 and Table II) . This increase was selective in that the steady-state levels of mRNA for GAPDH, a gene constitutively expressed in these cells (31), were not altered by TGF-f31 (Fig. 2) . These results suggest that the expression of type I collagen genes is specifically upregulated by TGF-,3l at the transcriptional level. Mouse NIH-3T3 cell cultures were transfected with 10 Ag of the plasmid indicated using CaPO4/DNA co-precipitation method, followed by a 2-min glycerol shock. The cultures were placed in serum-free medium, and 3 h later, the cells were exposed to 10 ng/ml TGF-# I for 40 hours. The cells were then harvested and CAT activity was de- Human skin fibroblasts were exposed to TGF-31 (5 ng/ml) alone or in combination with IFN-y (1,000 U/ml) and/or TNF-a (10 ng/ml) for 24 h in DME supplemented with 1% FCS. The values represent absorbance values scanned from X-ray films of Northern blots (see Fig. 2 Table II) .
To test the effect of IFN-,y on proa2(I) collagen transcriptional activity, human skin fibroblasts were transfected with pMS-3.5 CAT and incubated with IFN--y (1,000 U/ml). The results indicated only a slight suppression ( -17%) ofthe CAT activity (Table III) . Also, exposure of human skin fibroblasts transfected with proa2(I) collagen promoter/CAT gene construct to TGF-f,1 (5 ng/ml) and IFN-,y (1,000 U/ml) indicated that there was only a slight decrease (-30%) in the CAT activity in comparison to that noted with cells treated with TGF-4 I alone (Table IV) . Similarly, simultaneous exposure of transfected NIH-3T3 cells to 5 ng/ml of TGF-,B1 and 1,000 U/ml of IFN-,y had a slightly suppressing effect (-10%) on the TGF-,3l induced enhancement of proa2(I) collagen promoter activity (Table IV) . Thus, the suppression of type I collagen gene expression by IFN-y, as demonstrated on the mRNA level, appears not to be transcriptionally mediated and potentially revolves around the stability and turnover of the newly synthesized collagen mRNA.
TNF-a was similarly tested in human skin fibroblast and mouse NIH-3T3 cell cultures. Exposure of human skin fibroblasts transfected with pMS-3.5/CAT to 10 ng/ml of human recombinant TNF-a resulted in -83% inhibition of the proa2(I) collagen promoter activity, while TNF-a did not have a significant effect on the expression of pSV2CAT (Table III) . This observation suggested that TNF-a exerts its inhibitory effects on type I collagen gene expression at the transcriptional level. To test this hypothesis, skin fibroblasts were exposed to TGF-,31 (5 ng/ml) alone or in combination with TNF-a (10 ng/ml). As expected, TGF-13I induced a 2.2-4.8-fold elevation in endogenous type I collagen mRNA levels (Table II, Exp. 2). This stimulation was inhibited by TNF-a (10 ng/ml), which suppressed type I collagen mRNA steady-state abundance ap- proximately to the same levels that were seen in control cultures (Table II) . Interestingly, IFN-'y (1,000 U/ml) together with TNF-a (10 ng/ml) did not further decrease the proa I(I) collagen mRNA levels in TGF-g I treated cells, as compared to the effect noted with TNF-a alone (Table II) . Again, incubation with growth factors did not change the transfection efficiency, as determined by the plasmid copy number (32 the same level noted in untreated control cells (Fig. 3 gen deposition can lead to fibrosis of internal organs, as for , IV). These results indicated that TNF-a is a potent example, in the case of pulmonary fibrosis or liver cirrhosis.
Oftype I collagen gene expression and that it exerts its Also, skin is often affected by fibrotic processes. The prototype marily at the transcriptional level. In support of this of fibrotic diseases is progressive systemic sclerosis, a generalas the observation that co-treatment of transfected ized connective tissue disorder that involves not only the skin TNF-a and IFN-"y completely abolished the activabut also the lungs, heart, kidneys, and the gastrointestinal oa2(I) collagen promoter by TGF-# I in human skin tract. Several previous studies have indicated that activation of s ( Fig. 3 and Table IV ). Similar results were obtained collagen biosynthetic pathway plays mechanistically a role NIH-3T3 cell cultures, although the suppression of leading to deposition of collagen. For example, collagen biopromoter activity was less than that in human skin synthesis, as determined by the formation of radioactive hys (Table IV) . These results suggest synergistic inhibidroxyproline in fibroblast cultures established from these pave I collagen gene expression by IFN-'y and TNF-a.
tients, is increased (19) . Furthermore (15, 16) . Also, IFN-,y has been shown to reduce collagen accumulation in experimental fibrosis in animals (38) . On the basis of these observations, it has been suggested that interferons might potentially serve as a therapeutic modality to counteract collagen accumulation in fibrotic diseases (39) . (40) have demonstrated that stabilization of mouse proa 1(I) collagen mRNA also plays a role in TGF-f I -induced enhancement of collagen gene expression. In the human skin fibroblast system utilized in our study, the principal effect appears to be on the transcriptional level of type I procollagen gene expression. This conclusion was supported, in part, by the observation that TGF-#3I did not alter the CAT activity in the cells transfected with pSV2CAT construct, indicating that TGF-,# had no effect on the stability of CAT mRNA or protein.
TNF-a and IFN-y were both shown to counteract the TGF-f 1-induced enhancement of type I procollagen gene expression, as determined at the mRNA steady-state level. The results suggested, however, that the mechanism of inhibition was different: TNF-a appeared to affect type I procollagen gene expression on the transcriptional level, while IFN-'y appeared to exert its effect primarily through destabilization of the mRNA. These conclusions were supported by the observation that TNF-a had no effect on CAT activity in cells transfected with pSV2CAT, suggesting that neither the SV40 promoter nor CAT mRNA is susceptible to modulation by this polypeptide factor. However, IFN-y reduced the CAT activity in these cells to about half of that noted in the controls suggesting generalized enhancement of mRNA turnover. It should be noted that the growth factor effects in NIH-3T3 cells were obtained in serum-free medium. Similar results were obtained in human skin fibroblasts even though these cultures were supplemented with 1% fetal calf serum, indicating that endogenous factors present in serum did not interfere with the growth factor effects. These observations are in agreement with previous studies which have used culture media with different concentrations of fetal calf serum, varying from 0 to 10% (8-11, 15, 16 ).
An interesting observation was the synergistic effect of TNF-a and IFN-'y on proa2(I) collagen promoter activity ( Fig.  3 and Table IV) . A potential explanation for this synergism is provided by the previous finding that IFN--y can increase the number of TNF-a receptors in cultured cells, thus making these cells more susceptible to TNF-a modulation (41) . These observations would suggest that a combination of polypeptide factors, such as TNF-a and IFN-,y, would provide a potential approach for a more efficient pharmacologic suppression of collagen accumulation in fibrotic diseases than afforded by either one of the peptide factors alone.
